Health-related quality of life (HRQOL) results from PRESTO (AFT-19), a phase 3 randomized trial of intensification of androgen blockade in patients with high-risk biochemically relapsed castration sensitive prostate cancer.
- Citation:
- J Clin Oncol vol 24 (16_suppl) 5006
- Meeting Instance:
- ASCO 2024
- Year:
- 2024
- Type:
- Abstract
- Sub type:
- Oral
- Funding:
- AFT
- Endpoint:
- Secondary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epreprint
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- None
- Pharmas:
- JNJ
- Grants:
- AFT
- Corr. Author:
- Authors:
- Ronald C Chen Gina L Mazza Briant F Fruth Han Xiao Joel Picus Mary-Ellen Taplin Tanya Dorff Leonard Appleman Douglas Weckstein Akash Patnaik Alan Bryce Daniel Shevrin James L Mohler Daniel Anderson Arpit Rao Alan Tan Charles J Ryan Scott E Eggener Michael J Morris Rahul Aggarwal
- Networks:
- CA043, CA136, IL018, KANSAS, LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-MO011, LAPS-NY016, LAPS-NY158, LAPS-PA015, METROMIN, MN022, NH038, TN008, TX041
- Study
- AFT-19
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: